文献速递心境障碍

双相躁狂药物治疗:双盲随机对照试验的系统综述与网络荟萃分析

Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
PubMed 文献 · Mol Psychiatry · 2021-10-12

该系统综述与随机效应网络荟萃分析纳入72项双盲随机对照试验(n=16442),比较23种药物与安慰剂对成人急性躁狂的疗效、可接受性、耐受性和安全性。结果显示阿立哌唑、奥氮平、喹硫平和利培酮在可接受性上优于安慰剂,多种抗精神病药、卡马西平、锂盐、他莫昔芬和丙戊酸盐在疗效上优于安慰剂。

要点

  • 阿立哌唑、奥氮平、喹硫平和利培酮在可接受性上优于安慰剂。
  • 多种抗精神病药、卡马西平、锂盐、他莫昔芬和丙戊酸盐在疗效上优于安慰剂。
  • 托吡酯的全因停药率高于安慰剂。

核心结论

  • 这些抗精神病药、卡马西平、锂盐、他莫昔芬和丙戊酸盐对急性躁狂有效;但仅阿立哌唑、奥氮平、喹硫平和利培酮的可接受性优于安慰剂。

研究设计与样本

  • 系统综述与随机效应模型网络荟萃分析,检索PubMed、Cochrane Library和Embase至2021年3月14日。
  • 纳入成人躁狂口服药物单药治疗≥10天的随机对照试验,排除允许使用抗精神病药作为补救药物的研究。
  • 共纳入72项双盲随机对照试验,涉及23种药物和安慰剂,平均研究持续时间3.96±2.39周,n=16442,平均年龄39.55岁,男性占50.93%。

主要发现

  • 与安慰剂相比,阿立哌唑、阿塞那平、卡马西平、卡利拉嗪、氟哌啶醇、锂盐、奥氮平、帕利哌酮、喹硫平、利培酮、他莫昔芬、丙戊酸盐和齐拉西酮在治疗反应上更优(N=56,n=14503)。
  • 与安慰剂相比,阿立哌唑、奥氮平、喹硫平和利培酮的全因停药率更低;托吡酯的全因停药率更高(N=70,n=16324)。
  • 与安慰剂相比,阿立哌唑、阿塞那平、卡马西平、卡利拉嗪、氟哌啶醇、锂盐、奥氮平、帕利哌酮、喹硫平、利培酮、他莫昔芬、丙戊酸盐和齐拉西酮在躁狂症状改善上更优(N=61,n=15466)。
  • 与安慰剂相比,阿立哌唑、阿塞那平、卡马西平、卡利拉嗪、氟哌啶醇、锂盐、奥氮平、帕利哌酮、喹硫平、利培酮、丙戊酸盐和齐拉西酮因无效停药率更低(N=50,n=14284)。

关键数值与推荐

  • 主要结局为治疗反应(疗效)和全因停药(可接受性)。
  • 次要结局为躁狂症状改善和因无效停药。

临床怎么用

  • 对于成人急性躁狂,可选用证据支持有效的药物包括多种抗精神病药、卡马西平、锂盐、他莫昔芬和丙戊酸盐。
  • 若需兼顾可接受性,阿立哌唑、奥氮平、喹硫平和利培酮优于安慰剂。
  • 托吡酯的全因停药率高于安慰剂,提示其可接受性较差。

局限性

  • 平均研究持续时间较短(3.96±2.39周),可能限制长期结论的推广。
  • 排除允许使用抗精神病药作为补救药物的研究,可能影响结果的外推性。
  • 仅纳入口服药物单药治疗研究,未涵盖联合治疗或非口服制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A systematic review and random-effects model network meta-analysis was conducted to compare the efficacy, acceptability, tolerability, and safety of pharmacological interventions for adults with acute bipolar mania. We searched PubMed, the Cochrane Library, and Embase databases for eligible studies published before March 14, 2021. Randomized controlled trials (RCTs) of oral medication monotherapy lasting ≥10 days in adults with mania were included, and studies that allowed the use of antipsychotics as a rescue medication during a trial were excluded. The primary outcomes were response to treatment (efficacy) and all-cause discontinuation (acceptability). The secondary outcomes were the improvement of mania symptoms and discontinuation due to inefficacy. Of the 79 eligible RCTs, 72 double-blind RCTs of 23 drugs and a placebo were included in the meta-analysis (mean study duration = 3.96 ± 2.39 weeks, n = 16442, mean age = 39.55 years, with 50.93% males). Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone outperformed response to treatment (N = 56, n = 14503); aripiprazole, olanzapine, quetiapine, and risperidone had lower all-cause discontinuation; however, topiramate had higher all-cause discontinuation (N = 70, n = 16324). Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone outperformed the improvement of mania symptoms (N = 61, n = 15466), and aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, valproate, and ziprasidone had lower discontinuation due to inefficacy (N = 50, n = 14284). In conclusions, these antipsychotics, carbamazepine, lithium, tamoxifen, and valproate were effective for acute mania. However, only aripiprazole, olanzapine, quetiapine, and risperidone had better acceptability than the placebo.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kishi T, Ikuta T, Matsuda Y, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2021. PMID: 34642461. doi:10.1038/s41380-021-01334-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。